Ignite Creation Date:
2024-05-05 @ 5:01 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00367887
Status:
COMPLETED
Last Update Posted:
2013-02-11
First Post:
2006-08-21
Brief Title:
A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
A Phase 2 Randomized Open-Label Study Of The Safety Antiviral Activity And Pharmacokinetics Of HCV-796 Administered In Combination With Peginterferon Alfa 2B Peg-Intron Plus Ribavirin Rebetol Versus Peg-Intron Plus Rebetol In Subjects With Hepatitis C Virus Genotype 1 Infection
Status:
COMPLETED
Status Verified Date:
2013-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase 2 randomized open-label study comparing the safety antiviral activity and pharmacokinetics of HCV-796 administered in combination with peginterferon alfa 2B Peg-Intron plus concomitant Rebetol vs Peg-Intron plus Rebetol in Hepatitis C Virus HCV genotype
1-infected subjects who are either naive to treatment or who have previously failed treatment non-responders
1-infected subjects who are either naive to treatment or who have previously failed treatment non-responders
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| B3381001 | None | None | None |